KR102242391B1 - 오심 및 구토의 관리용 조성물 - Google Patents

오심 및 구토의 관리용 조성물 Download PDF

Info

Publication number
KR102242391B1
KR102242391B1 KR1020167004284A KR20167004284A KR102242391B1 KR 102242391 B1 KR102242391 B1 KR 102242391B1 KR 1020167004284 A KR1020167004284 A KR 1020167004284A KR 20167004284 A KR20167004284 A KR 20167004284A KR 102242391 B1 KR102242391 B1 KR 102242391B1
Authority
KR
South Korea
Prior art keywords
delete delete
pyridoxine
pharmaceutically acceptable
release
component
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020167004284A
Other languages
English (en)
Korean (ko)
Other versions
KR20160033201A (ko
Inventor
마농 브랑데릭
쟝-뤽 쌩-옹쥬
미셸르 갈로
에릭 제르베
Original Assignee
듀체스나이 아이엔씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50877783&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102242391(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 듀체스나이 아이엔씨 filed Critical 듀체스나이 아이엔씨
Publication of KR20160033201A publication Critical patent/KR20160033201A/ko
Application granted granted Critical
Publication of KR102242391B1 publication Critical patent/KR102242391B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyridine Compounds (AREA)
KR1020167004284A 2013-07-22 2014-03-13 오심 및 구토의 관리용 조성물 Expired - Fee Related KR102242391B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361856971P 2013-07-22 2013-07-22
US61/856,971 2013-07-22
PCT/CA2014/050231 WO2015010194A1 (en) 2013-07-22 2014-03-13 Composition for the management of nausea and vomiting

Publications (2)

Publication Number Publication Date
KR20160033201A KR20160033201A (ko) 2016-03-25
KR102242391B1 true KR102242391B1 (ko) 2021-04-21

Family

ID=50877783

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167004284A Expired - Fee Related KR102242391B1 (ko) 2013-07-22 2014-03-13 오심 및 구토의 관리용 조성물

Country Status (28)

Country Link
US (3) US10028941B2 (https=)
EP (1) EP3024466B1 (https=)
JP (1) JP6379194B2 (https=)
KR (1) KR102242391B1 (https=)
CN (1) CN105492013B (https=)
AR (1) AR097023A1 (https=)
AU (1) AU2014295765B2 (https=)
BR (1) BR112016001474A2 (https=)
CA (1) CA2847022C (https=)
CL (1) CL2016000154A1 (https=)
CY (1) CY1120386T1 (https=)
DK (1) DK3024466T3 (https=)
EA (1) EA029690B1 (https=)
ES (1) ES2670619T3 (https=)
HU (1) HUE039131T2 (https=)
IL (1) IL243638B (https=)
MX (1) MX366760B (https=)
MY (1) MY191347A (https=)
NO (1) NO3086669T3 (https=)
NZ (1) NZ716017A (https=)
PL (1) PL3024466T3 (https=)
PT (1) PT3024466T (https=)
SA (1) SA516370443B1 (https=)
SG (1) SG11201600122RA (https=)
TW (2) TWI654977B (https=)
UY (1) UY35674A (https=)
WO (1) WO2015010194A1 (https=)
ZA (1) ZA201600383B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX355912B (es) 2012-02-22 2018-05-04 Duchesnay Inc Formulación de doxilamina y piridoxina y/o sus metabolitos o sales.
SG11201600122RA (en) 2013-07-22 2016-02-26 Duchesnay Inc Composition for the management of nausea and vomiting
US9526703B2 (en) 2014-08-29 2016-12-27 Duchesnay Inc. Plurimodal release formulation of doxylamine and pyridoxine and/or metabolites or salts thereof
US10244873B2 (en) 2015-10-01 2019-04-02 Isee Store Innovations, Llc Adjustable product display system and method

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002543106A (ja) 1999-05-03 2002-12-17 ドラッグテック コーポレイション 抗悪心組成物および方法
US7704542B2 (en) 2001-09-12 2010-04-27 Xanodyne Pharmaceuticals, Inc. Vitamin/mineral compositions with DHA

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8518301D0 (en) 1985-07-19 1985-08-29 Fujisawa Pharmaceutical Co Hydrodynamically explosive systems
GB8524001D0 (en) 1985-09-30 1985-11-06 Glaxo Group Ltd Pharmaceutical composition
US4842867A (en) 1986-05-09 1989-06-27 Alza Corporation Pulsed drug delivery of doxylamine
IT1201136B (it) 1987-01-13 1989-01-27 Resa Farma Compressa per uso farmaceutico atta al rilascio in tempi successivi di sostanze attive
US5110597A (en) 1987-06-25 1992-05-05 Alza Corporation Multi-unit delivery system
US5017381A (en) 1990-05-02 1991-05-21 Alza Corporation Multi-unit pulsatile delivery system
US5387421A (en) 1991-01-31 1995-02-07 Tsrl, Inc. Multi stage drug delivery system
NZ242065A (en) 1991-03-26 1996-06-25 Csl Ltd Delayed release implant having a degradable or rupturable polymeric coating
US5260068A (en) 1992-05-04 1993-11-09 Anda Sr Pharmaceuticals Inc. Multiparticulate pulsatile drug delivery system
US5260069A (en) 1992-11-27 1993-11-09 Anda Sr Pharmaceuticals Inc. Pulsatile particles drug delivery system
DE19716732C2 (de) 1997-03-07 1999-03-25 Max Delbrueck Centrum Spezifische Magnetosomen, Verfahren zu ihrer Herstellung und ihre Verwendung
US5840329A (en) 1997-05-15 1998-11-24 Bioadvances Llc Pulsatile drug delivery system
US7744916B2 (en) * 1997-06-11 2010-06-29 Umd, Inc. Coated vaginal device for delivery of anti-migraine and anti-nausea drugs
FR2772615B1 (fr) 1997-12-23 2002-06-14 Lipha Comprime multicouche pour la liberation instantanee puis prolongee de substances actives
US6531152B1 (en) 1998-09-30 2003-03-11 Dexcel Pharma Technologies Ltd. Immediate release gastrointestinal drug delivery system
WO2000059479A1 (en) 1999-04-06 2000-10-12 Pharmaquest Ltd. Pharmaceutical dosage form for pulsatile delivery of methylphenidate
US6632451B2 (en) 1999-06-04 2003-10-14 Dexcel Pharma Technologies Ltd. Delayed total release two pulse gastrointestinal drug delivery system
WO2001037721A2 (en) 1999-11-22 2001-05-31 The Research Foundation Of State University Of New York Magnetic nanoparticles for selective therapy
US6627223B2 (en) 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems
US6500457B1 (en) 2000-08-14 2002-12-31 Peirce Management, Llc Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent
US6924273B2 (en) 2000-10-03 2005-08-02 Scott W. Pierce Chondroprotective/restorative compositions and methods of use thereof
CA2350195C (en) 2000-12-20 2003-06-10 Duchesnay Inc. Rapid onset formulation of pyridoxine hydrochloride and doxylamine succinate
WO2002055058A2 (en) 2001-01-09 2002-07-18 Microchips, Inc. Flexible microchip devices for ophthalmic and other applications
US6997863B2 (en) 2001-07-25 2006-02-14 Triton Biosystems, Inc. Thermotherapy via targeted delivery of nanoscale magnetic particles
CA2392486A1 (en) 2002-07-05 2002-12-08 Duchesnay Inc. Pharmaceutical dosage form bearing pregnancy-friendly indicia
DE60336727D1 (de) 2002-08-16 2011-05-26 Microchips Inc Vorrichtung mit kontrollierter abgabe und verfahren
GB0229725D0 (en) 2002-12-19 2003-01-29 Univ Wales Medicine Haplotype partitioning and growth hormone SNPs
US20100221321A1 (en) 2003-02-27 2010-09-02 Innercap Technologies, Inc. Apparatus And Methods For Delivering A Plurality Of Medicaments For Management Of Co-Morbid Diseases, Illnesses Or Conditions
JP5107041B2 (ja) 2004-09-01 2012-12-26 マイクロチップス・インコーポレーテッド レザバ内容物の制御された放出または曝露のための、マルチキャップレザバデバイス
GB0502475D0 (en) 2005-02-07 2005-03-16 Sb Pharmco Inc Novel compositions
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
US20070141147A1 (en) 2005-12-21 2007-06-21 Auriga Laboratories, Inc. Sequential release pharmaceutical formulations
US20090004281A1 (en) 2007-06-26 2009-01-01 Biovail Laboratories International S.R.L. Multiparticulate osmotic delivery system
CA2713128C (en) 2008-01-25 2016-04-05 Gruenenthal Gmbh Pharmaceutical dosage form
KR101190708B1 (ko) 2010-03-12 2012-10-12 주식회사 대웅제약 모사프리드 또는 이의 염을 포함하는 서방형 약학 조성물
WO2011124953A2 (en) 2010-04-07 2011-10-13 Lupin Limited Controlled release pharmaceutical compositions of tapentadol
US8486453B2 (en) 2010-06-22 2013-07-16 Twi Pharmaceuticals, Inc. Controlled release compositions with reduced food effect
CA2825917C (en) 2011-02-14 2016-08-30 The Procter & Gamble Company Filmcoated solid dosage forms comprising honey in the coating
CA2835293C (en) 2011-06-08 2020-08-18 Sti Pharma, Llc Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration
MX355912B (es) 2012-02-22 2018-05-04 Duchesnay Inc Formulación de doxilamina y piridoxina y/o sus metabolitos o sales.
WO2013123569A1 (en) 2012-02-22 2013-08-29 Duchesnay Inc. Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof
SG11201600122RA (en) 2013-07-22 2016-02-26 Duchesnay Inc Composition for the management of nausea and vomiting

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002543106A (ja) 1999-05-03 2002-12-17 ドラッグテック コーポレイション 抗悪心組成物および方法
US7704542B2 (en) 2001-09-12 2010-04-27 Xanodyne Pharmaceuticals, Inc. Vitamin/mineral compositions with DHA

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Therapeutic drug monitoring, 2011, 33(1) p115-119.

Also Published As

Publication number Publication date
CA2847022A1 (en) 2014-06-03
NZ716017A (en) 2020-07-31
AU2014295765A1 (en) 2016-02-04
AR097023A1 (es) 2016-02-10
MX366760B (es) 2019-07-23
UY35674A (es) 2014-12-31
TWI654977B (zh) 2019-04-01
HUE039131T2 (hu) 2018-12-28
US10028941B2 (en) 2018-07-24
NO3086669T3 (https=) 2018-06-23
CA2847022C (en) 2015-04-07
EP3024466A4 (en) 2017-03-29
WO2015010194A1 (en) 2015-01-29
HK1218264A1 (en) 2017-02-10
JP2016527237A (ja) 2016-09-08
US9439920B2 (en) 2016-09-13
EP3024466B1 (en) 2018-04-04
TW201720442A (zh) 2017-06-16
EA029690B1 (ru) 2018-04-30
CY1120386T1 (el) 2019-07-10
SG11201600122RA (en) 2016-02-26
US20150025033A1 (en) 2015-01-22
ES2670619T3 (es) 2018-05-31
US20150025032A1 (en) 2015-01-22
JP6379194B2 (ja) 2018-08-22
BR112016001474A2 (pt) 2020-04-14
KR20160033201A (ko) 2016-03-25
IL243638A0 (en) 2016-02-29
EP3024466A1 (en) 2016-06-01
PT3024466T (pt) 2018-07-13
MY191347A (en) 2022-06-17
CN105492013B (zh) 2018-09-18
US9452181B2 (en) 2016-09-27
MX2016000884A (es) 2016-05-05
CL2016000154A1 (es) 2016-08-05
AU2014295765B2 (en) 2019-02-14
DK3024466T3 (en) 2018-06-06
US20160143892A1 (en) 2016-05-26
IL243638B (en) 2019-09-26
ZA201600383B (en) 2017-11-29
SA516370443B1 (ar) 2018-08-08
EA201690149A1 (ru) 2016-06-30
TWI589292B (zh) 2017-07-01
TW201513860A (zh) 2015-04-16
PL3024466T3 (pl) 2018-08-31
CN105492013A (zh) 2016-04-13

Similar Documents

Publication Publication Date Title
US9937132B2 (en) Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof
WO2013123569A1 (en) Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof
KR102242391B1 (ko) 오심 및 구토의 관리용 조성물
HK1218264B (en) Composition for the management of nausea and vomiting
HK1247571B (en) Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof
HK1247571A1 (en) Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof

Legal Events

Date Code Title Description
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

X091 Application refused [patent]
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20240415

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20240415